On August 21, 2021, the Food and Drug Administration tweeted – “You are not a horse. You are not a cow. Seriously, y’all. Stop it.” Ivermectin is an anthelmintic – used to destroy parasitic worms – yet, some individuals are using it off-label (and off-animal) to treat COVID-19. This interactive debate between an attorney and pharmacist reviews both the clinical and legal aspects of this situation.

Upon successful completion of this knowledge-based CPE course, pharmacists should be able to:
1. Identify the clinical uses for ivermectin – both human and animal.
2. Discuss the regulatory status of ivermectin for human and animal use in the United States.
3. Describe potential legal liability for dispensing ivermectin as prophylaxis or treatment of COVID-19, and the potential legal liability for declining to dispense ivermectin as prophylaxis or treatment of COVID-19.
4. Explain the regulatory limits for off-label use of FDA-approved drug products to treat COVID-19.

David B. Brushwood, R.Ph, J.D.
Senior Lecturer, The University of Wyoming School of Pharmacy
CEimpact’s Expert in Residence, Pharmacy Law

John A Galdo (Jake), PharmD, MBA, BCPS, BCGP
CEimpact

David B. Brushwood and Jake Galdo report no actual or potential conflicts of interest in relation to this continuing pharmacy education course.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: September 9, 2021
Planned Expiration Date: September 9, 2024

This course is provided for educational purposes. CEimpact is not a law firm and does not provide legal advice of any kind. For legal advice, please contact a licensed attorney. 

Copyright 2021, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.